Cometriq (cabozantinib)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- cabozantinib
- Company
- Ipsen Pharma
- Status
- Authorised
- Therapeutic area
- Thyroid Neoplasms
- CHMP opinion
- Thu 19 Dec 2013
- EU approval
- Fri 21 Mar 2014
- Designations
- Orphan
- Application
- EMEA/H/C/002640
- ATC
- L01XE
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Cabometyx Authorised · Ipsen Pharma
- 🇺🇸 Omcazio Approved · Handa Oncol
Follow Cometriq
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.